Report Interpretation
Covering the latest research from top Wall Street investment banks
Report InterpretationHilo Research

AccoTest (688200) Report Interpretation

Goldman Sachs expects local GPU-related demand and STS8600 shipment expansion to support AccoTest’s growth. It raises 2026-28E revenue and net-income forecasts but retains a Neutral rating and Rmb630 target price.

InstitutionGoldman Sachs
Date20260914
CompanyAccoTest
Ticker688200.SH
IndustrySemiconductors
RatingNeutral

Summary

Goldman Sachs expects local GPU-related demand and STS8600 shipment expansion to support AccoTest’s growth. It raises 2026-28E revenue and net-income forecasts but retains a Neutral rating and Rmb630 target price.

Neutral; 12-month target price Rmb630.00; current price Rmb346.52; implied upside 81.8%.
AccoTestSTS8600Semiconductor test equipmentLocal GPUChina WFEEarnings revisionNeutral
  • China semiconductor-equipment capex is forecast to grow 13%/15%/15% in 2026-28E, supporting WFE spending growth of 13%/20%/15%.
  • AccoTest has begun small-volume STS8600 shipments and continues product verification with local CPU and GPU customers.
  • Goldman Sachs raises 2026-28E revenue estimates by 3%/7%/10% and net-income estimates by 15%/5%/3%.
  • 3Q26E revenue is forecast at Rmb512m, up 27% year-on-year and 10% quarter-on-quarter, with gross margin expected to remain at 74% quarter-on-quarter.
  • The Rmb630 12-month target price and Neutral rating are unchanged.

Report Interpretation

Overview

This earnings review assesses how AccoTest’s STS8600 tester rollout and rising domestic GPU-related semiconductor-equipment demand affect its growth outlook. Goldman Sachs lifts earnings forecasts on stronger revenue expectations but maintains Neutral and its Rmb630 12-month target price.

Core views

Goldman Sachs links AccoTest’s outlook to a favorable China semiconductor-equipment spending backdrop. It forecasts China semiconductor capex growth of 13% in 2026E and 15% in both 2027E and 2028E, reaching US$68bn in 2028E. This is expected to support China wafer-fab-equipment spending growth of 13%/20%/15% across 2026-28E. The report expects demand from domestic major foundries, IDMs and OSATs to rise as customers migrate to advanced nodes and expand capacity for AI-related end demand. At the company level, AccoTest has started small-volume shipments of its STS8600 testing tool and is continuing product verification with local CPU and GPU clients. Goldman Sachs believes this customer-validation process and the expanding client base can support a shipment ramp over coming years. It raises its 2027E-28E STS8600 shipment assumptions because of strong orders on hand and customer expansion. However, tight supplies of upstream materials are identified as a near-term constraint on shipment growth. For 3Q26E, the report forecasts revenue of Rmb512m, up 27% year-on-year and 10% quarter-on-quarter, driven by testing-equipment shipments. Gross margin is expected to remain broadly flat quarter-on-quarter at 74%, reflecting a largely unchanged product mix. AccoTest reported 2Q26 revenue of Rmb467m, 11% above Goldman Sachs estimates and 9% above consensus, rising 39% year-on-year and 72% quarter-on-quarter. Gross profit was Rmb347m, while operating income was Rmb177m and pretax income Rmb360m. Following the 2Q26 result, Goldman Sachs raises 2026E-28E revenue forecasts by 3%/7%/10%, to Rmb1,801m/Rmb2,284m/Rmb2,840m, chiefly from a higher STS8600 contribution. Net-income forecasts increase by 15%/5%/3%, to Rmb856m/Rmb957m/Rmb1,218m. Gross-margin assumptions are largely unchanged at 73.9%/73.0%/72.8%, while operating-margin forecasts are reduced because higher R&D spending is needed to broaden the product line and client base. The valuation remains unchanged despite the higher forecasts. Goldman Sachs derives its 12-month Rmb630 target price using a 64x 2030E discounted P/E multiple, selected from the relationship between peer P/E multiples and the sum of forward net-income growth and operating margin. It discounts the multiple back to 2027E using an 11% cost of equity. Goldman Sachs maintains Neutral, citing the unchanged valuation framework alongside the improved growth outlook.

Analysis framework

The report starts with China semiconductor-capex and wafer-fab-equipment demand, then connects this industry backdrop to AccoTest’s STS8600 customer verification, orders and shipment potential. It incorporates the 2Q26 result into revised revenue, margin, R&D and net-income forecasts, then applies a peer-referenced discounted P/E framework to retain the target price and rating.

Methodology notes

  • Valuation methodsP/E and PEG Valuation

    Discounted P/E valuation using a 64x 2030E target P/E, discounted back to 2027E at an 11% cost of equity.

    Goldman Sachs sets the target multiple with reference to the relationship between peers’ P/E multiples, forward net-income growth and operating margin, then discounts it to produce the 12-month target price.

  • Industry AnalysisSupply-demand framework

    China semiconductor-capex and wafer-fab-equipment spending outlook linked to demand from foundries, IDMs and OSATs.

    The report uses expected industry investment, advanced-node migration and AI-related capacity expansion to explain the demand environment for AccoTest’s testing equipment.

Asset mapping & comparison

Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).

  • AccoTest (688200.SS)
    Primary covered company expected to benefit from domestic semiconductor-equipment demand and STS8600 adoption by local CPU and GPU clients.
    Strengths
    Small-volume STS8600 shipments have begun; customer verification, strong orders on hand and client-base expansion support a future shipment ramp.
    Weaknesses
    Higher R&D spending raises operating-expense ratios and lowers operating-margin forecasts versus prior estimates.
    Comparison
    Its target P/E multiple is derived from the relationship between peer P/E multiples, forward net-income growth and operating margin.
    Risks
    Higher or lower China WFE capex, higher or lower SPE localization, and stronger or milder market competition.

Key data

  • China semiconductor capex growth13% / 15% / 15% in 2026E-28E; US$68bn in 2028EGoldman Sachs forecast supporting the domestic semiconductor-equipment outlook.
  • China WFE spending growth13% / 20% / 15% in 2026E-28EExpected to be supported by semiconductor-capex growth.
  • 2Q26 revenueRmb467m11% above Goldman Sachs estimates, 9% above consensus, 39% year-on-year growth and 72% quarter-on-quarter growth.
  • 3Q26E revenueRmb512mForecast to rise 27% year-on-year and 10% quarter-on-quarter.
  • 3Q26E gross margin74%Expected to remain flat quarter-on-quarter on a largely unchanged product mix.
  • 2026E-28E revenue revisions+3% / +7% / +10%Driven mainly by a higher STS8600 contribution.
  • 2026E-28E net-income revisions+15% / +5% / +3%Mainly reflects higher revenue forecasts.
  • 12-month target priceRmb630.00Based on 64x 2030E discounted P/E and an 11% cost of equity.

Impact & implications

The report argues that AccoTest is positioned to benefit from expanding domestic semiconductor-equipment demand and local CPU/GPU testing needs. Higher expected STS8600 contribution raises the earnings outlook, but supply constraints and increased R&D spending temper the near-term operating outlook; Goldman Sachs therefore retains Neutral.

Risks

  • China wafer-fab-equipment capex could be higher or lower than expected.
  • The semiconductor-production-equipment localization rate could be higher or lower than expected.
  • Market competition could be stronger or milder than expected.
  • Tight upstream-material supply could constrain near-term shipment growth.

What to watch

  • STS8600 product verification and shipment progress with local CPU and GPU customers.
  • Order backlog and client-base expansion for STS8600.
  • China semiconductor capex and WFE spending trends.
  • Upstream-material supply conditions and their effect on shipments.
  • R&D spending and resulting operating-margin development.
Zhejiang ICP No. 2022035445-5
Disclaimer: Market data, charts, indicators, research views, and other information provided on this website are intended solely for information display, research communication, and educational reference. They should not be regarded as personalized investment advice, securities recommendations, trading instructions, solicitations, or guarantees of return. While we strive to improve the reliability of our data and content, such information may still be subject to delays, errors, incompleteness, or untimely updates due to source differences, methodological limitations, system processing, or market volatility. Users should exercise independent judgment based on their own circumstances and bear all risks and responsibilities arising from the use of this website.

Settings

Sign in to view recent logins